The term artificial pancreas sounds like science fiction. But it is not, at least not entirely. FDA-approved closed-loop insulin delivery systems exist today and are changing lives for people with Type 1 Diabetes. Here is what you need to know.
What Does a Pancreas Actually Do?
In a person without diabetes, the pancreas performs a continuous, automatic balancing act: detecting blood glucose levels and releasing precisely the right amount of insulin to keep those levels in a healthy range, after meals, during exercise, overnight, and in response to stress.
In T1D, the immune system has destroyed the cells that do this work. Every person with T1D must manually replicate this function, checking blood sugar, calculating insulin doses, and injecting or pumping insulin dozens of times per day.
An artificial pancreas automates this process.
How a Closed-Loop System Works
A modern closed-loop insulin delivery system has three components:
- A CGM that measures blood glucose continuously every few minutes
- An insulin pump that delivers insulin through a small catheter under the skin
- A control algorithm that interprets CGM data and automatically adjusts insulin delivery
These three components communicate with each other constantly. When blood sugar rises after a meal, the algorithm increases insulin delivery. When blood sugar drops during exercise, it reduces or suspends delivery. The system never sleeps, even when the person wearing it does.
What the Research Shows
- Significant improvements in time in range, the percentage of time blood sugar stays within healthy limits
- Dramatic reductions in dangerous overnight low blood sugar events
- Reduced burden of daily diabetes management
- Improvements in sleep quality, which has major downstream effects on overall health
The Current Limitations
- Systems handle meals imperfectly because they react to rising blood sugar rather than anticipating it
- They struggle with rapid exercise-related glucose changes
- Still require the user to announce meals and make manual corrections in many situations
- Often cost $5,000 to $10,000 per year when insulin costs are included
- Not accessible to the majority of T1D patients worldwide
What Comes Next
Researchers are working on fully closed-loop systems that require no manual input at all. Dual-hormone systems that deliver both insulin and glucagon are in clinical trials.
Further ahead, non-invasive biosensor technology, like the work being done by KFD’s own research team, could eliminate the need for under-skin sensors entirely, making closed-loop systems smaller, less intrusive, and more affordable.
The artificial pancreas is not finished. But it is real. And it is getting better every year.
